The U.S. Food and Drug Administration (FDA) has issued a warning to consumers to not purchase or use Skin-Cap aerosol spray products, as they may contain undisclosed steroids.
Per the agency, testing identified a high-potency immunosuppressive and anti-inflammatory glucocorticosteroid in Skin-Cap aerosol spray products that is not disclosed on the label or packaging.
Skip-Cap Skin/Scalp Treatment Indications
The Skin-Cap products are marketed as treatments for:
- psoriasis,
- seborrheic and typical dermatitis,
- typical eczema,
- painful lichen,
- skin redness,
- dandruff,
- itching and
- irritation of the skin.
They are sold by Chemigroup France, formerly known as Cheminova Laboratories, on skincap.com, amazon.com and walmart.com.
Potential Adverse Reactions, and Bigger Health Issues with Topical Corticosteroids
The FDA reports that long-term use of topical corticosteroids, like glucocorticosteroids, can cause health problems such as skin thinning (atrophy) and skin reactions; and, if used on large body areas, may lead to increased blood glucose (sugar) levels, changes in blood pressure, damage to bones, psychiatric problems and changes in hormone levels (adrenal dysfunction).
As such, the agency advises consumers using this product to contact their health care professional to determine the best course of action, and to abruptly stop using the product, as it may cause adverse reactions.
No Skin-Cap Product Adverse Events Reported
The FDA reports it is not currently aware of any adverse events related to Skin-Cap aerosol spray products. However, should they arise, health care professionals and consumers should report adverse events or side effects related to the use of this product to FDA's MedWatch Safety Information and Adverse Event Reporting Program by:
